Long-term effects of dalfampridine in patients with multiple sclerosis

Dalfampridine is the extended-release formulation of 4-aminopyridine and is approved for the symptomatic treatment of impaired mobility in patients with multiple sclerosis. Our aim was to examine the short- and long-term effects of treatment with dalfampridine on motoric and cognitive assessment par...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of the neurological sciences Vol. 337; no. 1-2; pp. 18 - 24
Main Authors:	Ruck, T., Bittner, S., Simon, O.J., Göbel, K., Wiendl, H., Schilling, M., Meuth, S.G.
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 15.02.2014
Subjects:	4-Aminopyridine - therapeutic use Cognition Disorders - drug therapy Cognition Disorders - etiology Dalfampridine Disability Evaluation Drug Delivery Systems Electroencephalography Evoked Potentials - drug effects Evoked Potentials - physiology Fatigue Female Follow-Up Studies Humans Long-term treatment Male Middle Aged Mobility Multiple Sclerosis - complications Multiple Sclerosis - drug therapy Neurology Potassium Channel Blockers - therapeutic use Severity of Illness Index Statistics, Nonparametric Time Factors Walking - physiology Walking ability Mobility Fatigue Dalfampridine Long-term treatment MS Walking ability
ISSN:	0022-510X, 1878-5883, 1878-5883
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Dalfampridine is the extended-release formulation of 4-aminopyridine and is approved for the symptomatic treatment of impaired mobility in patients with multiple sclerosis. Our aim was to examine the short- and long-term effects of treatment with dalfampridine on motoric and cognitive assessment parameters of multiple sclerosis (MS) patients over 9–12months. Fifty-two patients with MS with an EDSS between 4.0 and 7.0 and impaired mobility were evaluated for parameters of walking ability, MSFC, cognitive and motor fatigue and evoked potentials at treatment initiation with dalfampridine as well as 2weeks and after 9–12months later. Thirty out of fifty-two patients (~60%) were still on treatment after 9–12months. Two weeks after treatment initiation, significant ameliorations could be found for T25FW, maximum walking distance as well as motoric and cognitive fatigue which still persisted after 9–12months. In contrast significant effects for velocity were observed only after 2weeks, for improvement in PASAT only after 9–12months. A tendency for improvement of somatosensory evoked potentials was found in a subset of patients. Dalfampridine shows positive short- and long-term effects on motoric and cognitive assessment parameters in an open-label observational study in a cohort of patients with MS.
AbstractList	Dalfampridine is the extended-release formulation of 4-aminopyridine and is approved for the symptomatic treatment of impaired mobility in patients with multiple sclerosis. Our aim was to examine the short- and long-term effects of treatment with dalfampridine on motoric and cognitive assessment parameters of multiple sclerosis (MS) patients over 9-12 months.BACKGROUND/OBJECTIVEDalfampridine is the extended-release formulation of 4-aminopyridine and is approved for the symptomatic treatment of impaired mobility in patients with multiple sclerosis. Our aim was to examine the short- and long-term effects of treatment with dalfampridine on motoric and cognitive assessment parameters of multiple sclerosis (MS) patients over 9-12 months.Fifty-two patients with MS with an EDSS between 4.0 and 7.0 and impaired mobility were evaluated for parameters of walking ability, MSFC, cognitive and motor fatigue and evoked potentials at treatment initiation with dalfampridine as well as 2 weeks and after 9-12 months later.METHODSFifty-two patients with MS with an EDSS between 4.0 and 7.0 and impaired mobility were evaluated for parameters of walking ability, MSFC, cognitive and motor fatigue and evoked potentials at treatment initiation with dalfampridine as well as 2 weeks and after 9-12 months later.Thirty out of fifty-two patients (~60%) were still on treatment after 9-12 months. Two weeks after treatment initiation, significant ameliorations could be found for T25FW, maximum walking distance as well as motoric and cognitive fatigue which still persisted after 9-12 months. In contrast significant effects for velocity were observed only after 2 weeks, for improvement in PASAT only after 9-12 months. A tendency for improvement of somatosensory evoked potentials was found in a subset of patients.RESULTSThirty out of fifty-two patients (~60%) were still on treatment after 9-12 months. Two weeks after treatment initiation, significant ameliorations could be found for T25FW, maximum walking distance as well as motoric and cognitive fatigue which still persisted after 9-12 months. In contrast significant effects for velocity were observed only after 2 weeks, for improvement in PASAT only after 9-12 months. A tendency for improvement of somatosensory evoked potentials was found in a subset of patients.Dalfampridine shows positive short- and long-term effects on motoric and cognitive assessment parameters in an open-label observational study in a cohort of patients with MS.CONCLUSIONDalfampridine shows positive short- and long-term effects on motoric and cognitive assessment parameters in an open-label observational study in a cohort of patients with MS. Abstract Background/objective Dalfampridine is the extended-release formulation of 4-aminopyridine and is approved for the symptomatic treatment of impaired mobility in patients with multiple sclerosis. Our aim was to examine the short- and long-term effects of treatment with dalfampridine on motoric and cognitive assessment parameters of multiple sclerosis (MS) patients over 9–12 months. Methods Fifty-two patients with MS with an EDSS between 4.0 and 7.0 and impaired mobility were evaluated for parameters of walking ability, MSFC, cognitive and motor fatigue and evoked potentials at treatment initiation with dalfampridine as well as 2 weeks and after 9–12 months later. Results Thirty out of fifty-two patients (~ 60%) were still on treatment after 9–12 months. Two weeks after treatment initiation, significant ameliorations could be found for T25FW, maximum walking distance as well as motoric and cognitive fatigue which still persisted after 9–12 months. In contrast significant effects for velocity were observed only after 2 weeks, for improvement in PASAT only after 9–12 months. A tendency for improvement of somatosensory evoked potentials was found in a subset of patients. Conclusion Dalfampridine shows positive short- and long-term effects on motoric and cognitive assessment parameters in an open-label observational study in a cohort of patients with MS. Dalfampridine is the extended-release formulation of 4-aminopyridine and is approved for the symptomatic treatment of impaired mobility in patients with multiple sclerosis. Our aim was to examine the short- and long-term effects of treatment with dalfampridine on motoric and cognitive assessment parameters of multiple sclerosis (MS) patients over 9-12 months. Fifty-two patients with MS with an EDSS between 4.0 and 7.0 and impaired mobility were evaluated for parameters of walking ability, MSFC, cognitive and motor fatigue and evoked potentials at treatment initiation with dalfampridine as well as 2 weeks and after 9-12 months later. Thirty out of fifty-two patients (~60%) were still on treatment after 9-12 months. Two weeks after treatment initiation, significant ameliorations could be found for T25FW, maximum walking distance as well as motoric and cognitive fatigue which still persisted after 9-12 months. In contrast significant effects for velocity were observed only after 2 weeks, for improvement in PASAT only after 9-12 months. A tendency for improvement of somatosensory evoked potentials was found in a subset of patients. Dalfampridine shows positive short- and long-term effects on motoric and cognitive assessment parameters in an open-label observational study in a cohort of patients with MS. Dalfampridine is the extended-release formulation of 4-aminopyridine and is approved for the symptomatic treatment of impaired mobility in patients with multiple sclerosis. Our aim was to examine the short- and long-term effects of treatment with dalfampridine on motoric and cognitive assessment parameters of multiple sclerosis (MS) patients over 9–12months. Fifty-two patients with MS with an EDSS between 4.0 and 7.0 and impaired mobility were evaluated for parameters of walking ability, MSFC, cognitive and motor fatigue and evoked potentials at treatment initiation with dalfampridine as well as 2weeks and after 9–12months later. Thirty out of fifty-two patients (~60%) were still on treatment after 9–12months. Two weeks after treatment initiation, significant ameliorations could be found for T25FW, maximum walking distance as well as motoric and cognitive fatigue which still persisted after 9–12months. In contrast significant effects for velocity were observed only after 2weeks, for improvement in PASAT only after 9–12months. A tendency for improvement of somatosensory evoked potentials was found in a subset of patients. Dalfampridine shows positive short- and long-term effects on motoric and cognitive assessment parameters in an open-label observational study in a cohort of patients with MS.
Author	Bittner, S. Schilling, M. Ruck, T. Simon, O.J. Wiendl, H. Meuth, S.G. Göbel, K.
Author_xml	– sequence: 1 givenname: T. surname: Ruck fullname: Ruck, T. – sequence: 2 givenname: S. surname: Bittner fullname: Bittner, S. – sequence: 3 givenname: O.J. surname: Simon fullname: Simon, O.J. – sequence: 4 givenname: K. surname: Göbel fullname: Göbel, K. – sequence: 5 givenname: H. surname: Wiendl fullname: Wiendl, H. – sequence: 6 givenname: M. surname: Schilling fullname: Schilling, M. – sequence: 7 givenname: S.G. surname: Meuth fullname: Meuth, S.G. email: sven.meuth@ukmuenster.de
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/24290498$$D View this record in MEDLINE/PubMed
BookMark	eNqNkkFv1DAQhS1URLeFH8AF5cglYSaJE0dISKiitNJKHACJm-W1x-DgOIudFPXf49W2l0oUTj7M-541780ZOwlzIMZeIlQI2L0ZqzGkqgZsKsQKEJ-wDYpelFyI5oRtAOq65AjfTtlZSiMAdEIMz9hp3dYDtIPYsMvtHL6XC8WpIGtJL6mYbWGUt2raR2dcoMKFYq8WRyEPf7vlRzGtfnF7T0XSnuKcXHrOnlrlE724e8_Z18sPXy6uyu2nj9cX77elbgdcyg7INrrloLC3dW96MkitgLZVvWh3nFRTY2MQON91aNQOUMOgeyBhDSjdnLPXR999nH-tlBY5uaTJexVoXpNEjl3PoUf-H9IcxyCwwyx9dSdddxMZmRefVLyV9zFlQX8U6LxtimSldkuOZA5LVM5LBHkoRI4yFyIPhUhEmQvJJD4g780fY94eGcpJ3jiKMumcvibjYm5Imtk9Sr97QGvvgtPK_6RbSuO8xpArkihTLUF-PhzJ4UawgQZaqLPB8HeDf3z-B_rsyig
CitedBy_id	crossref_primary_10_1016_j_jns_2015_06_008 crossref_primary_10_1016_j_msard_2019_101489 crossref_primary_10_1155_2014_802307 crossref_primary_10_1212_WNL_0000000000007970 crossref_primary_10_1002_cpdd_574 crossref_primary_10_1016_j_neucli_2017_02_004 crossref_primary_10_1016_j_nrl_2015_11_013 crossref_primary_10_1016_j_jns_2018_10_004 crossref_primary_10_1177_17562864251321696 crossref_primary_10_1007_s40263_020_00734_4 crossref_primary_10_1016_j_nrleng_2015_11_019 crossref_primary_10_1016_j_jneuroim_2020_577227 crossref_primary_10_1159_000442348 crossref_primary_10_1517_17425255_2015_993315 crossref_primary_10_1007_s40265_021_01526_w crossref_primary_10_1177_1352458518815795 crossref_primary_10_1007_s00415_015_7797_1 crossref_primary_10_3389_fnmol_2017_00344 crossref_primary_10_1002_brb3_559 crossref_primary_10_1007_s11940_016_0412_7 crossref_primary_10_1097_WNF_0000000000000130 crossref_primary_10_1212_WNL_0000000000003656 crossref_primary_10_2217_nmt_2020_0024 crossref_primary_10_1016_j_jns_2016_06_019 crossref_primary_10_1016_j_msard_2018_12_026 crossref_primary_10_1177_1352458517720043 crossref_primary_10_1159_000480729 crossref_primary_10_1016_j_msard_2016_07_019 crossref_primary_10_1007_s12325_020_01606_5 crossref_primary_10_1016_j_msard_2021_103213 crossref_primary_10_1111_nyas_12512 crossref_primary_10_1177_2040622319835136 crossref_primary_10_1177_1352458520924267 crossref_primary_10_1007_s10072_023_06795_9 crossref_primary_10_1007_s00415_018_8796_9 crossref_primary_10_1007_s40263_018_0536_2 crossref_primary_10_1080_14656566_2019_1623879 crossref_primary_10_1016_j_clinph_2016_04_010 crossref_primary_10_1016_j_clineuro_2015_08_023
Cites_doi	10.1016/S0306-4522(96)00477-0 10.1177/1352458510386998 10.1007/BF00810346 10.1097/01.wco.0000413319.87092.19 10.1016/j.pharmthera.2005.10.006 10.1016/j.acn.2005.07.006 10.1111/j.0953-816X.2004.03164.x 10.1038/283570a0 10.1177/1352458508088916 10.1016/j.expneurol.2013.05.016 10.1212/WNL.45.11.1956 10.1191/135248506ms1244oa 10.1006/exnr.1997.6706 10.1016/j.jns.2006.06.031 10.1002/ana.22240 10.1185/03007995.2011.583229 10.1007/s004150170222 10.1093/brain/123.1.171 10.1016/0006-8993(96)00667-1 10.1177/1352458509348519 10.1002/ana.20703 10.1056/NEJMra052130 10.1212/WNL.44.9.1701 10.1212/WNL.33.11.1444 10.1002/mus.880030202 10.1191/135245801701567050 10.1017/S0317167100048691 10.1016/S0140-6736(09)60442-6
ContentType	Journal Article
Copyright	2013 Elsevier B.V. Elsevier B.V. Copyright © 2013 Elsevier B.V. All rights reserved.
Copyright_xml	– notice: 2013 Elsevier B.V. – notice: Elsevier B.V. – notice: Copyright © 2013 Elsevier B.V. All rights reserved.
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7TK
DOI	10.1016/j.jns.2013.11.011
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Neurosciences Abstracts
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic Neurosciences Abstracts
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1878-5883
EndPage	24
ExternalDocumentID	24290498 10_1016_j_jns_2013_11_011 S0022510X13030402 1_s2_0_S0022510X13030402
Genre	Journal Article
GroupedDBID	--- --K --M .1- .FO .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AATTM AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABFNM ABFRF ABGSF ABIVO ABJNI ABLJU ABMAC ABMZM ABTEW ABUDA ABXDB ACDAQ ACGFO ACGFS ACIEU ACIUM ACLOT ACRLP ACVFH ADBBV ADCNI ADEZE ADUVX AEBSH AEFWE AEHWI AEIPS AEKER AENEX AEUPX AEVXI AFPUW AFRHN AFTJW AFXIZ AGHFR AGUBO AGWIK AGYEJ AHHHB AIEXJ AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX AXJTR BKOJK BLXMC BNPGV CS3 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA IHE J1W KOM L7B LX8 M29 M2V M41 MO0 MOBAO N9A O-L O9- OAUVE OP~ OZT P-8 P-9 P2P PC. Q38 ROL RPZ SAE SCC SDF SDG SDP SEL SES SPCBC SSH SSN SSU SSZ T5K Z5R ~G- ~HD .55 .GJ 29L AACTN AAQXK ABWVN ACRPL ADMUD ADNMO AFCTW AFJKZ AFKWA AGRDE AJOXV AKRLJ AMFUW ASPBG AVWKF AZFZN FEDTE FGOYB G-2 HDW HMK HMO HMQ HVGLF HZ~ R2- RIG SEW SNS WUQ X7M ZGI ZXP AADPK AAIAV ABLVK ABYKQ AJBFU DOVZS LCYCR ZA5 9DU AAYXX AGQPQ AIGII APXCP CITATION AGCQF AGRNS CGR CUY CVF ECM EIF NPM 7X8 7TK
ID	FETCH-LOGICAL-c491t-60ef3c450a17f27d7ed1e48044a784b5ea3213d1055b61dab01c09c70e8fd0ac3
ISICitedReferencesCount	43
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000332808700005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0022-510X 1878-5883
IngestDate	Sun Sep 28 03:05:27 EDT 2025 Thu Oct 02 20:30:06 EDT 2025 Mon Jul 21 05:55:54 EDT 2025 Sat Nov 29 05:07:04 EST 2025 Tue Nov 18 21:50:19 EST 2025 Fri Feb 23 02:32:54 EST 2024 Sun Feb 23 10:18:48 EST 2025 Tue Oct 14 19:31:08 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Issue	1-2
Keywords	Mobility Fatigue Dalfampridine Long-term treatment MS Walking ability
Language	English
License	Copyright © 2013 Elsevier B.V. All rights reserved.
LinkModel	OpenURL
MergedId	FETCHMERGED-LOGICAL-c491t-60ef3c450a17f27d7ed1e48044a784b5ea3213d1055b61dab01c09c70e8fd0ac3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1
PMID	24290498
PQID	1500698161
PQPubID	23479
PageCount	7
ParticipantIDs	proquest_miscellaneous_1516750715 proquest_miscellaneous_1500698161 pubmed_primary_24290498 crossref_citationtrail_10_1016_j_jns_2013_11_011 crossref_primary_10_1016_j_jns_2013_11_011 elsevier_sciencedirect_doi_10_1016_j_jns_2013_11_011 elsevier_clinicalkeyesjournals_1_s2_0_S0022510X13030402 elsevier_clinicalkey_doi_10_1016_j_jns_2013_11_011
PublicationCentury	2000
PublicationDate	2014-02-15
PublicationDateYYYYMMDD	2014-02-15
PublicationDate_xml	– month: 02 year: 2014 text: 2014-02-15 day: 15
PublicationDecade	2010
PublicationPlace	Netherlands
PublicationPlace_xml	– name: Netherlands
PublicationTitle	Journal of the neurological sciences
PublicationTitleAlternate	J Neurol Sci
PublicationYear	2014
Publisher	Elsevier B.V
Publisher_xml	– name: Elsevier B.V
References	Heesen, Bohm, Reich, Kasper, Goebel, Gold (bb0015) 2008; 14 Dunn, Blight (bb0025) 2011; 27 Gobel, Wedell, Herrmann, Wachsmuth, Pankratz, Bittner (bb0120) 2013; 248C Fisk, Pontefract, Ritvo, Archibald, Murray (bb0130) 1994; 21 Tombaugh (bb0135) 2006; 21 Meyer, Britton, Benecke, Bischoff, Machetanz, Conrad (bb0085) 1992; 239 Meuth, Bittner, Seiler, Gobel, Wiendl (bb0090) 2011; 17 Smith, Felts, John (bb0045) 2000; 123 Kurtzke (bb0095) 1983; 33 Shi, Kelly, Blight (bb0155) 1997; 148 Krupp, Coyle, Doscher, Miller, Cross, Jandorf (bb0105) 1995; 45 NHS Commisioning Board (bb0060) Smits, Emmen, Bertelsmann, Kulig, van Loenen, Polman (bb0115) 1994; 44 Fehlings, Nashmi (bb0145) 1996; 736 Kallmann, Fackelmann, Toyka, Rieckmann, Reiners (bb0080) 2006; 12 Frohman, Racke, Raine (bb0005) 2006; 354 Comi, Leocani, Rossi, Colombo (bb0125) 2001; 248 Rossini, Pasqualetti, Pozzilli, Grasso, Millefiorini, Graceffa (bb0110) 2001; 7 Goodman, Brown, Krupp, Schapiro, Schwid, Cohen (bb0050) 2009; 373 Fischer, Jak, Kniker, Rudick, Cutter (bb0070) 2001 Judge, Bever (bb0140) 2006; 111 Daroff, Fenichel, Jankovic, Mazziota (bb0010) 2012 Goodman, Brown, Edwards, Krupp, Schapiro, Cohen (bb0055) 2010; 68 Sherratt, Bostock, Sears (bb0030) 1980; 283 Miller, Rhoades (bb0020) 2012 Karimi-Abdolrezaee, Eftekharpour, Fehlings (bb0150) 2004; 19 Kim, Goldner, Sanders (bb0040) 1980; 3 Amato, Portaccio (bb0100) 2007; 259 Penner, Raselli, Stocklin, Opwis, Kappos, Calabrese (bb0075) 2009; 15 Shi, Blight (bb0035) 1997; 77 Polman, Reingold, Edan, Filippi, Hartung, Kappos (bb0065) 2005; 58 Rossini (10.1016/j.jns.2013.11.011_bb0110) 2001; 7 Tombaugh (10.1016/j.jns.2013.11.011_bb0135) 2006; 21 Goodman (10.1016/j.jns.2013.11.011_bb0050) 2009; 373 Kallmann (10.1016/j.jns.2013.11.011_bb0080) 2006; 12 NHS Commisioning Board (10.1016/j.jns.2013.11.011_bb0060) Shi (10.1016/j.jns.2013.11.011_bb0035) 1997; 77 Frohman (10.1016/j.jns.2013.11.011_bb0005) 2006; 354 Smith (10.1016/j.jns.2013.11.011_bb0045) 2000; 123 Judge (10.1016/j.jns.2013.11.011_bb0140) 2006; 111 Dunn (10.1016/j.jns.2013.11.011_bb0025) 2011; 27 Amato (10.1016/j.jns.2013.11.011_bb0100) 2007; 259 Meyer (10.1016/j.jns.2013.11.011_bb0085) 1992; 239 Comi (10.1016/j.jns.2013.11.011_bb0125) 2001; 248 Miller (10.1016/j.jns.2013.11.011_bb0020) 2012 Fisk (10.1016/j.jns.2013.11.011_bb0130) 1994; 21 Karimi-Abdolrezaee (10.1016/j.jns.2013.11.011_bb0150) 2004; 19 Fischer (10.1016/j.jns.2013.11.011_bb0070) 2001 Gobel (10.1016/j.jns.2013.11.011_bb0120) 2013; 248C Daroff (10.1016/j.jns.2013.11.011_bb0010) 2012 Goodman (10.1016/j.jns.2013.11.011_bb0055) 2010; 68 Penner (10.1016/j.jns.2013.11.011_bb0075) 2009; 15 Krupp (10.1016/j.jns.2013.11.011_bb0105) 1995; 45 Fehlings (10.1016/j.jns.2013.11.011_bb0145) 1996; 736 Kim (10.1016/j.jns.2013.11.011_bb0040) 1980; 3 Shi (10.1016/j.jns.2013.11.011_bb0155) 1997; 148 Meuth (10.1016/j.jns.2013.11.011_bb0090) 2011; 17 Smits (10.1016/j.jns.2013.11.011_bb0115) 1994; 44 Sherratt (10.1016/j.jns.2013.11.011_bb0030) 1980; 283 Kurtzke (10.1016/j.jns.2013.11.011_bb0095) 1983; 33 Polman (10.1016/j.jns.2013.11.011_bb0065) 2005; 58 Heesen (10.1016/j.jns.2013.11.011_bb0015) 2008; 14
References_xml	– volume: 123 start-page: 171 year: 2000 end-page: 184 ident: bb0045 article-title: Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension publication-title: Brain – volume: 248C start-page: 62 year: 2013 end-page: 71 ident: bb0120 article-title: 4-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosis publication-title: Exp Neurol – volume: 259 start-page: 118 year: 2007 end-page: 122 ident: bb0100 article-title: Clinical outcome measures in multiple sclerosis publication-title: J Neurol Sci – volume: 111 start-page: 224 year: 2006 end-page: 259 ident: bb0140 article-title: Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment publication-title: Pharmacol Ther – volume: 68 start-page: 494 year: 2010 end-page: 502 ident: bb0055 article-title: A phase 3 trial of extended release oral dalfampridine in multiple sclerosis publication-title: Ann Neurol – volume: 7 start-page: 354 year: 2001 end-page: 358 ident: bb0110 article-title: Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine publication-title: Mult Scler – volume: 77 start-page: 553 year: 1997 end-page: 562 ident: bb0035 article-title: Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord publication-title: Neuroscience – volume: 373 start-page: 732 year: 2009 end-page: 738 ident: bb0050 article-title: Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial publication-title: Lancet – volume: 3 start-page: 105 year: 1980 end-page: 111 ident: bb0040 article-title: Facilitatory effects of 4-aminopyridine on normal neuromuscular transmission publication-title: Muscle Nerve – volume: 736 start-page: 135 year: 1996 end-page: 145 ident: bb0145 article-title: Changes in pharmacological sensitivity of the spinal cord to potassium channel blockers following acute spinal cord injury publication-title: Brain Res – volume: 248 start-page: 174 year: 2001 end-page: 179 ident: bb0125 article-title: Physiopathology and treatment of fatigue in multiple sclerosis publication-title: J Neurol – volume: 44 start-page: 1701 year: 1994 end-page: 1705 ident: bb0115 article-title: The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study publication-title: Neurology – ident: bb0060 article-title: Clinical commissioning policy statement: Fampridine for, multiple sclerosis – volume: 21 start-page: 9 year: 1994 end-page: 14 ident: bb0130 article-title: The impact of fatigue on patients with multiple sclerosis publication-title: Can J Neurol Sci – year: 2001 ident: bb0070 article-title: Multiple Sclerosis Functional Composite (MSFC): administration and scoring manual – volume: 354 start-page: 942 year: 2006 end-page: 955 ident: bb0005 article-title: Multiple sclerosis — the plaque and its pathogenesis publication-title: N Engl J Med – volume: 21 start-page: 53 year: 2006 end-page: 76 ident: bb0135 article-title: A comprehensive review of the Paced Auditory Serial Addition Test (PASAT) publication-title: Arch Clin Neuropsychol – volume: 19 start-page: 577 year: 2004 end-page: 589 ident: bb0150 article-title: Temporal and spatial patterns of Kv1.1 and Kv1.2 protein and gene expression in spinal cord white matter after acute and chronic spinal cord injury in rats: implications for axonal pathophysiology after neurotrauma publication-title: Eur J Neurosci – volume: 27 start-page: 1415 year: 2011 end-page: 1423 ident: bb0025 article-title: Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis publication-title: Curr Med Res Opin – volume: 45 start-page: 1956 year: 1995 end-page: 1961 ident: bb0105 article-title: Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo publication-title: Neurology – volume: 15 start-page: 1509 year: 2009 end-page: 1517 ident: bb0075 article-title: The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue publication-title: Mult Scler – volume: 33 start-page: 1444 year: 1983 end-page: 1452 ident: bb0095 article-title: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) publication-title: Neurology – volume: 58 start-page: 840 year: 2005 end-page: 846 ident: bb0065 article-title: Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” publication-title: Ann Neurol – start-page: 92 year: 2012 end-page: 116 ident: bb0010 article-title: Bradley's neurology in clinical practice – volume: 239 start-page: 251 year: 1992 end-page: 255 ident: bb0085 article-title: Motor responses evoked by magnetic brain stimulation in psychogenic limb weakness: diagnostic value and limitations publication-title: J Neurol – volume: 17 start-page: 198 year: 2011 end-page: 203 ident: bb0090 article-title: Natalizumab restores evoked potential abnormalities in patients with relapsing–remitting multiple sclerosis publication-title: Mult Scler – volume: 12 start-page: 58 year: 2006 end-page: 65 ident: bb0080 article-title: Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis publication-title: Mult Scler – volume: 148 start-page: 495 year: 1997 end-page: 501 ident: bb0155 article-title: Conduction block in acute and chronic spinal cord injury: different dose–response characteristics for reversal by 4-aminopyridine publication-title: Exp Neurol – start-page: S4 year: 2012 end-page: S10 ident: bb0020 article-title: Treatment of relapsing–remitting multiple sclerosis: current approaches and unmet needs publication-title: Curr Opin Neurol – volume: 283 start-page: 570 year: 1980 end-page: 572 ident: bb0030 article-title: Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres publication-title: Nature – volume: 14 start-page: 988 year: 2008 end-page: 991 ident: bb0015 article-title: Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable publication-title: Mult Scler – volume: 77 start-page: 553 year: 1997 ident: 10.1016/j.jns.2013.11.011_bb0035 article-title: Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord publication-title: Neuroscience doi: 10.1016/S0306-4522(96)00477-0 – volume: 17 start-page: 198 year: 2011 ident: 10.1016/j.jns.2013.11.011_bb0090 article-title: Natalizumab restores evoked potential abnormalities in patients with relapsing–remitting multiple sclerosis publication-title: Mult Scler doi: 10.1177/1352458510386998 – ident: 10.1016/j.jns.2013.11.011_bb0060 – volume: 239 start-page: 251 year: 1992 ident: 10.1016/j.jns.2013.11.011_bb0085 article-title: Motor responses evoked by magnetic brain stimulation in psychogenic limb weakness: diagnostic value and limitations publication-title: J Neurol doi: 10.1007/BF00810346 – start-page: S4 issue: 25 Suppl. year: 2012 ident: 10.1016/j.jns.2013.11.011_bb0020 article-title: Treatment of relapsing–remitting multiple sclerosis: current approaches and unmet needs publication-title: Curr Opin Neurol doi: 10.1097/01.wco.0000413319.87092.19 – volume: 111 start-page: 224 year: 2006 ident: 10.1016/j.jns.2013.11.011_bb0140 article-title: Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2005.10.006 – volume: 21 start-page: 53 year: 2006 ident: 10.1016/j.jns.2013.11.011_bb0135 article-title: A comprehensive review of the Paced Auditory Serial Addition Test (PASAT) publication-title: Arch Clin Neuropsychol doi: 10.1016/j.acn.2005.07.006 – volume: 19 start-page: 577 year: 2004 ident: 10.1016/j.jns.2013.11.011_bb0150 article-title: Temporal and spatial patterns of Kv1.1 and Kv1.2 protein and gene expression in spinal cord white matter after acute and chronic spinal cord injury in rats: implications for axonal pathophysiology after neurotrauma publication-title: Eur J Neurosci doi: 10.1111/j.0953-816X.2004.03164.x – volume: 283 start-page: 570 year: 1980 ident: 10.1016/j.jns.2013.11.011_bb0030 article-title: Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres publication-title: Nature doi: 10.1038/283570a0 – volume: 14 start-page: 988 year: 2008 ident: 10.1016/j.jns.2013.11.011_bb0015 article-title: Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable publication-title: Mult Scler doi: 10.1177/1352458508088916 – volume: 248C start-page: 62 year: 2013 ident: 10.1016/j.jns.2013.11.011_bb0120 article-title: 4-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosis publication-title: Exp Neurol doi: 10.1016/j.expneurol.2013.05.016 – volume: 45 start-page: 1956 year: 1995 ident: 10.1016/j.jns.2013.11.011_bb0105 article-title: Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo publication-title: Neurology doi: 10.1212/WNL.45.11.1956 – start-page: 92 year: 2012 ident: 10.1016/j.jns.2013.11.011_bb0010 – volume: 12 start-page: 58 year: 2006 ident: 10.1016/j.jns.2013.11.011_bb0080 article-title: Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis publication-title: Mult Scler doi: 10.1191/135248506ms1244oa – volume: 148 start-page: 495 year: 1997 ident: 10.1016/j.jns.2013.11.011_bb0155 article-title: Conduction block in acute and chronic spinal cord injury: different dose–response characteristics for reversal by 4-aminopyridine publication-title: Exp Neurol doi: 10.1006/exnr.1997.6706 – volume: 259 start-page: 118 year: 2007 ident: 10.1016/j.jns.2013.11.011_bb0100 article-title: Clinical outcome measures in multiple sclerosis publication-title: J Neurol Sci doi: 10.1016/j.jns.2006.06.031 – volume: 68 start-page: 494 year: 2010 ident: 10.1016/j.jns.2013.11.011_bb0055 article-title: A phase 3 trial of extended release oral dalfampridine in multiple sclerosis publication-title: Ann Neurol doi: 10.1002/ana.22240 – volume: 27 start-page: 1415 year: 2011 ident: 10.1016/j.jns.2013.11.011_bb0025 article-title: Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis publication-title: Curr Med Res Opin doi: 10.1185/03007995.2011.583229 – volume: 248 start-page: 174 year: 2001 ident: 10.1016/j.jns.2013.11.011_bb0125 article-title: Physiopathology and treatment of fatigue in multiple sclerosis publication-title: J Neurol doi: 10.1007/s004150170222 – volume: 123 start-page: 171 issue: Pt 1 year: 2000 ident: 10.1016/j.jns.2013.11.011_bb0045 article-title: Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension publication-title: Brain doi: 10.1093/brain/123.1.171 – volume: 736 start-page: 135 year: 1996 ident: 10.1016/j.jns.2013.11.011_bb0145 article-title: Changes in pharmacological sensitivity of the spinal cord to potassium channel blockers following acute spinal cord injury publication-title: Brain Res doi: 10.1016/0006-8993(96)00667-1 – year: 2001 ident: 10.1016/j.jns.2013.11.011_bb0070 – volume: 15 start-page: 1509 year: 2009 ident: 10.1016/j.jns.2013.11.011_bb0075 article-title: The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue publication-title: Mult Scler doi: 10.1177/1352458509348519 – volume: 58 start-page: 840 year: 2005 ident: 10.1016/j.jns.2013.11.011_bb0065 article-title: Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” publication-title: Ann Neurol doi: 10.1002/ana.20703 – volume: 354 start-page: 942 year: 2006 ident: 10.1016/j.jns.2013.11.011_bb0005 article-title: Multiple sclerosis — the plaque and its pathogenesis publication-title: N Engl J Med doi: 10.1056/NEJMra052130 – volume: 44 start-page: 1701 year: 1994 ident: 10.1016/j.jns.2013.11.011_bb0115 article-title: The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study publication-title: Neurology doi: 10.1212/WNL.44.9.1701 – volume: 33 start-page: 1444 year: 1983 ident: 10.1016/j.jns.2013.11.011_bb0095 article-title: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) publication-title: Neurology doi: 10.1212/WNL.33.11.1444 – volume: 3 start-page: 105 year: 1980 ident: 10.1016/j.jns.2013.11.011_bb0040 article-title: Facilitatory effects of 4-aminopyridine on normal neuromuscular transmission publication-title: Muscle Nerve doi: 10.1002/mus.880030202 – volume: 7 start-page: 354 year: 2001 ident: 10.1016/j.jns.2013.11.011_bb0110 article-title: Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine publication-title: Mult Scler doi: 10.1191/135245801701567050 – volume: 21 start-page: 9 year: 1994 ident: 10.1016/j.jns.2013.11.011_bb0130 article-title: The impact of fatigue on patients with multiple sclerosis publication-title: Can J Neurol Sci doi: 10.1017/S0317167100048691 – volume: 373 start-page: 732 year: 2009 ident: 10.1016/j.jns.2013.11.011_bb0050 article-title: Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(09)60442-6
SSID	ssj0006889
Score	2.2888958
Snippet	Dalfampridine is the extended-release formulation of 4-aminopyridine and is approved for the symptomatic treatment of impaired mobility in patients with... Abstract Background/objective Dalfampridine is the extended-release formulation of 4-aminopyridine and is approved for the symptomatic treatment of impaired...
SourceID	proquest pubmed crossref elsevier
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	18
SubjectTerms	4-Aminopyridine - therapeutic use Cognition Disorders - drug therapy Cognition Disorders - etiology Dalfampridine Disability Evaluation Drug Delivery Systems Electroencephalography Evoked Potentials - drug effects Evoked Potentials - physiology Fatigue Female Follow-Up Studies Humans Long-term treatment Male Middle Aged Mobility Multiple Sclerosis - complications Multiple Sclerosis - drug therapy Neurology Potassium Channel Blockers - therapeutic use Severity of Illness Index Statistics, Nonparametric Time Factors Walking - physiology Walking ability
Title	Long-term effects of dalfampridine in patients with multiple sclerosis
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S0022510X13030402 https://www.clinicalkey.es/playcontent/1-s2.0-S0022510X13030402 https://dx.doi.org/10.1016/j.jns.2013.11.011 https://www.ncbi.nlm.nih.gov/pubmed/24290498 https://www.proquest.com/docview/1500698161 https://www.proquest.com/docview/1516750715
Volume	337
WOSCitedRecordID	wos000332808700005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1878-5883 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0006889 issn: 0022-510X databaseCode: AIEXJ dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLa6DiFeEHfKZQoS4gEpk5M4sfM4UMutdEh0Ut6MEzsoVZd2TTft53Nc21k7aBkPvERVFMfVOd85_hyfC0KvgaQShSPhl0CufZKE0k9Lin0Zs1xn7NFSrYq4DuloxLIs_dbp_HC5MBdTWtfs8jKd_1dVwz1Qtk6d_Qd1ty-FG_AblA5XUDtcb6T44az-6WuHux6rIcW0FKfzRSUrUybE1lO1yW1tWGEDL4N1s2q2kFZNU1clMJ3LtCvoWsR8sRl7_a5aLq939_oOAFl5u-OrU6kPs9wEDHxZ_xAREB27bFIx1xIDwMSzdecamZIuDkU21dE4S-t4zbJrMql_c-jm28LkcFLr2upBdKhLrlr3vFE8e3TMByfDIR_3s_Gb-Zmv-4rp83fbZGUP7Yc0TlkX7R996mef29U6YSx1FeX1n3cn36sYwGuzbuMu2_YmK44yvofuWj15RwYU91FH1Q_Q7a82fOIhGrTY8Cw2vFnpbWDDq2rPYcPT2PAcNrwWG4_QyaA_fv_Rt400_IKkwdJPsCqjgsRYBLQMqaRKBoowTIigjOSxElEYRFL3Ss2TQIocBwVOC4oVKyUWRfQYdetZrZ4iL8gFSYiMNdMjUrNbFYtEyjAHgw_zooewExEvbJV53exkyl044YSDVLmWKuw-OUi1h962Q-amxMquh0Mnd-5yh2G144CXXYPonwapxpptwwPehBxzHboQahRoZgfLW9hDpB1pDcpQzb9N-MpBgoO71mdwolazc5go1rXBGeyzdj0TwDYeuH_cQ08MnlrBAKNOYVPPnt1g9HN058pOX6DucnGuXqJbxcWyahYHaI9m7MCawy9Cm8rf
linkProvider	Elsevier
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Long-term+effects+of+dalfampridine+in+patients+with+multiple+sclerosis&rft.jtitle=Journal+of+the+neurological+sciences&rft.au=Ruck%2C+T&rft.au=Bittner%2C+S&rft.au=Simon%2C+O+J&rft.au=Gobel%2C+K&rft.date=2014-02-15&rft.issn=0022-510X&rft.volume=337&rft.issue=1-2&rft.spage=18&rft.epage=24&rft_id=info:doi/10.1016%2Fj.jns.2013.11.011&rft.externalDBID=NO_FULL_TEXT
thumbnail_m	http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F0022510X%2FS0022510X14X00031%2Fcov150h.gif